376 related articles for article (PubMed ID: 27107440)
1. A bioinformatics approach for precision medicine off-label drug drug selection among triple negative breast cancer patients.
Cheng L; Schneider BP; Li L
J Am Med Inform Assoc; 2016 Jul; 23(4):741-9. PubMed ID: 27107440
[TBL] [Abstract][Full Text] [Related]
2. The evolving management of metastatic triple negative breast cancer.
Malhotra MK; Emens LA
Semin Oncol; 2020 Aug; 47(4):229-237. PubMed ID: 32563561
[TBL] [Abstract][Full Text] [Related]
3. Identification of selective cytotoxic and synthetic lethal drug responses in triple negative breast cancer cells.
Gautam P; Karhinen L; Szwajda A; Jha SK; Yadav B; Aittokallio T; Wennerberg K
Mol Cancer; 2016 May; 15(1):34. PubMed ID: 27165605
[TBL] [Abstract][Full Text] [Related]
4. High-throughput «Omics» technologies: New tools for the study of triple-negative breast cancer.
Judes G; Rifaï K; Daures M; Dubois L; Bignon YJ; Penault-Llorca F; Bernard-Gallon D
Cancer Lett; 2016 Nov; 382(1):77-85. PubMed ID: 26965997
[TBL] [Abstract][Full Text] [Related]
5. Triple-negative breast cancer: advancements in characterization and treatment approach.
Hurvitz S; Mead M
Curr Opin Obstet Gynecol; 2016 Feb; 28(1):59-69. PubMed ID: 26694831
[TBL] [Abstract][Full Text] [Related]
6. Proteomics as a Guide for Personalized Adjuvant Chemotherapy in Patients with Early Breast Cancer.
Lumachi F; Chiara GB; Foltran L; Basso SM
Cancer Genomics Proteomics; 2015; 12(6):385-90. PubMed ID: 26543084
[TBL] [Abstract][Full Text] [Related]
7. Refinement of Triple-Negative Breast Cancer Molecular Subtypes: Implications for Neoadjuvant Chemotherapy Selection.
Lehmann BD; Jovanović B; Chen X; Estrada MV; Johnson KN; Shyr Y; Moses HL; Sanders ME; Pietenpol JA
PLoS One; 2016; 11(6):e0157368. PubMed ID: 27310713
[TBL] [Abstract][Full Text] [Related]
8. Integrative exploration of genomic profiles for triple negative breast cancer identifies potential drug targets.
Wang X; Guda C
Medicine (Baltimore); 2016 Jul; 95(30):e4321. PubMed ID: 27472710
[TBL] [Abstract][Full Text] [Related]
9. Validation of a network-based strategy for the optimization of combinatorial target selection in breast cancer therapy: siRNA knockdown of network targets in MDA-MB-231 cells as an in vitro model for inhibition of tumor development.
Tilli TM; Carels N; Tuszynski JA; Pasdar M
Oncotarget; 2016 Sep; 7(39):63189-63203. PubMed ID: 27527857
[TBL] [Abstract][Full Text] [Related]
10. Guanylate-binding protein-1 is a potential new therapeutic target for triple-negative breast cancer.
Quintero M; Adamoski D; Reis LMD; Ascenção CFR; Oliveira KRS; Gonçalves KA; Dias MM; Carazzolle MF; Dias SMG
BMC Cancer; 2017 Nov; 17(1):727. PubMed ID: 29115931
[TBL] [Abstract][Full Text] [Related]
11. The Correlation Between PARP1 and BRCA1 in AR Positive Triple-negative Breast Cancer.
Luo J; Jin J; Yang F; Sun Z; Zhang W; Shi Y; Xu J; Guan X
Int J Biol Sci; 2016; 12(12):1500-1510. PubMed ID: 27994514
[TBL] [Abstract][Full Text] [Related]
12. Systems Medicine Design for Triple-Negative Breast Cancer and Non-Triple-Negative Breast Cancer Based on Systems Identification and Carcinogenic Mechanisms.
Yeh SJ; Hsu BJ; Chen BS
Int J Mol Sci; 2021 Mar; 22(6):. PubMed ID: 33802957
[TBL] [Abstract][Full Text] [Related]
13. Systems modelling of the EGFR-PYK2-c-Met interaction network predicts and prioritizes synergistic drug combinations for triple-negative breast cancer.
Shin SY; Müller AK; Verma N; Lev S; Nguyen LK
PLoS Comput Biol; 2018 Jun; 14(6):e1006192. PubMed ID: 29920512
[TBL] [Abstract][Full Text] [Related]
14. Identification of a novel inhibitor of triple-negative breast cancer cell growth by screening of a small-molecule library.
Fujita T; Mizukami T; Okawara T; Inoue K; Fujimori M
Breast Cancer; 2014 Nov; 21(6):738-47. PubMed ID: 23456737
[TBL] [Abstract][Full Text] [Related]
15. An integrated bioinformatics analysis to dissect kinase dependency in triple negative breast cancer.
Ryall KA; Kim J; Klauck PJ; Shin J; Yoo M; Ionkina A; Pitts TM; Tentler JJ; Diamond JR; Eckhardt SG; Heasley LE; Kang J; Tan AC
BMC Genomics; 2015; 16 Suppl 12(Suppl 12):S2. PubMed ID: 26681397
[TBL] [Abstract][Full Text] [Related]
16. New targets for triple-negative breast cancer.
Herold CI; Anders CK
Oncology (Williston Park); 2013 Sep; 27(9):846-54. PubMed ID: 24282978
[TBL] [Abstract][Full Text] [Related]
17. Triple-negative breast cancer: is there a treatment on the horizon?
Yao H; He G; Yan S; Chen C; Song L; Rosol TJ; Deng X
Oncotarget; 2017 Jan; 8(1):1913-1924. PubMed ID: 27765921
[TBL] [Abstract][Full Text] [Related]
18. Co-targeting poly(ADP-ribose) polymerase (PARP) and histone deacetylase (HDAC) in triple-negative breast cancer: Higher synergism in BRCA mutated cells.
Marijon H; Lee DH; Ding L; Sun H; Gery S; de Gramont A; Koeffler HP
Biomed Pharmacother; 2018 Mar; 99():543-551. PubMed ID: 29902865
[TBL] [Abstract][Full Text] [Related]
19. Histone deacetylase inhibitor, suberoylanilide hydroxamic acid (SAHA), enhances anti-tumor effects of the poly (ADP-ribose) polymerase (PARP) inhibitor olaparib in triple-negative breast cancer cells.
Min A; Im SA; Kim DK; Song SH; Kim HJ; Lee KH; Kim TY; Han SW; Oh DY; Kim TY; O'Connor MJ; Bang YJ
Breast Cancer Res; 2015 Mar; 17():33. PubMed ID: 25888415
[TBL] [Abstract][Full Text] [Related]
20. Personalized treatment in metastatic triple-negative breast cancer: The outlook in 2020.
Azim HA; Ghosn M; Oualla K; Kassem L
Breast J; 2020 Jan; 26(1):69-80. PubMed ID: 31872557
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
